BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

INTRODUCTION: Fucosyl-GM1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-986012 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal antibody that binds to fucosyl-GM1. METHODS: CA001-030 is a phase 1/2, first-in-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Quincy, Leighl, Natasha B., Surmont, Veerle, van Herpen, Carla, Sibille, Anne, Markman, Ben, Clarke, Stephen, Juergens, Rosalyn A., Rivera, Mirelis Acosta, Andelkovic, Vladimir, Rudin, Charles M., Snow, Stephanie, Kim, Dong-Wan, Sanatani, Michael, Lin, Hongxia, Sanghavi, Kinjal, Tannenbaum-Dvir, Sarah, Basciano, Paul, Lathers, Deanne, Urbanska, Katarzyna, Kollia, Georgia, He, Chunsheng, DiPiero, Andrew, Liu, Yu, Ready, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579497/
https://www.ncbi.nlm.nih.gov/pubmed/36275912
http://dx.doi.org/10.1016/j.jtocrr.2022.100400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579497/
https://www.ncbi.nlm.nih.gov/pubmed/36275912
http://dx.doi.org/10.1016/j.jtocrr.2022.100400

Ejemplares similares